The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $11,264,520 in first-year total cost, median $2,868,105.
Most frequent study sections
- Special Emphasis Panel[ZDA1 IXN-O (04)]2
- Special Emphasis Panel[ZDA1 IXN-O (09)]2
Most frequent institutions
- INTERVEXION THERAPEUTICS, LLC1
- OPIANT PHARMACEUTICALS, INC.1
- UNIVERSITY OF KENTUCKY1
- YALE UNIVERSITY1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Development of an intranasal, long duration opioid antagonist to treat opioid overdose1U01DA046093-01 | CRYSTAL, ROGER | OPIANT PHARMACEUTICALS, INC., CA | $2,551,346 | ZDA1 |
| 2018 | Development of Novel Therapeutics for Methamphetamine Abuse1U01DA043908-01A1 | DWOSKIN, LINDA P | UNIVERSITY OF KENTUCKY, KY | $926,568 | ZDA1 |
| 2017 | STAMPOUT: A Phase 2a Study of Antibody for Methamphetamine Outpatient Therapy1U01DA045366-01 | GENTRY, W BROOKSSTEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $4,601,742 | ZDA1 |
| 2017 | Fatty Acid Amide Hydrolase (FAAH) Inhibitor Treatment of Cannabis Use Disorder (CUD)1U01DA045372-01 | D'SOUZA, DEEPAK CYRIL | YALE UNIVERSITY, CT | $3,184,864 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.